Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA

Two decades since the discovery of the RNA interference (RNAi) pathway, we are now witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs. Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular barriers, requiring its enc...

Full description

Bibliographic Details
Main Authors: Roberta Guagliardo, Pieterjan Merckx, Agata Zamborlin, Lynn De Backer, Mercedes Echaide, Jesus Pérez-Gil, Stefaan C. De Smedt, Koen Raemdonck
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/11/9/431